EP 1720846 A1 20061115 - USE OF THIADIAZOLE UREA DERIVATIVES
Title (en)
USE OF THIADIAZOLE UREA DERIVATIVES
Title (de)
VERWENDUNG VON THIADIAZOLHARNSTOFFDERIVATEN
Title (fr)
UTILISATION DE DERIVES DE THIADIAZOLE-UREE
Publication
Application
Priority
- EP 2005000908 W 20050131
- DE 102004009933 A 20040226
Abstract (en)
[origin: DE102004009933A1] 1,3,4-Thiadiazole derivatives (I) are used to prepare medicaments for preventing or treating diseases in which the inhibition, regulation or modulation of kinase signal transduction plays a role. 1,3,4-Thiadiazole derivatives of formula (I) and their derivatives, solvates, salts and stereoisomers are used to prepare medicaments for preventing or treating diseases in which the inhibition, regulation or modulation of kinase signal transduction plays a role. Ar 1>phenyl, naphthyl, biphenylyl or Het, all optionally substituted with 1-4 of R 1>; Ar 2>phenyl, naphthyl, biphenylyl or Het, all optionally substituted with 1-4 of R 2>; Y : O, S, CHNO 2, C(CN) 2 or NR 4>; Z : O, S, CH 2(CH 2) n, (CH 2) nCHA, CHA(CH 2) n; CO, CHOH, (CHA) nO, (CH 2) nO, O(CHA) n, O(CH 2) n, (CH 2) nS, S(CH 2) n, (CH 2) nNH, NH(CH 2) n, (CH 2) nNA, NA(CH 2) n, CHHal or C(Hal) 2; Het : mono- or bicyclic heteroaryl with 1-4 N, O and/or S atoms; R 1>, R 2>A, Ar', OR 3>, SR 3>, OAr', SAr', N(R 3>) 2, NHAr', Hal, NO 2, CN, (CH 2) nCOOR 3>, (CH 2) nCON(R 3>) 2, COR 3>, SO mA, SO mAr', NHCOA, NHCOAr', NHSO mA. NHSO mAr', SO mN(R 3>) 2, O(CH 2) nN(R 3>) 2, O(CH 2) nNHR 3>, O(CH 2) nNA 2, O(CH 2) nC(Me) 2(CH 2) nN(R 3>) 2, NH(CH 2) n(CH 2) 2(CH 2) nN(R 3>) 2, O(CH 2) nN(R 3>)SO mA, O(CH 2) nN(R 3>)SO mN(R 3>)A, O(CH 2) nN(R 3>)SO mAr', (CH 2) nN(R 3>)SO mA, (CH 2) nN(R 3>)SO mN(R 3>)A, (CH 2) nN(R 3>)SO mAr', O(CH 2) nSO mA, O(CH 2) nSO mN(R 3>)A, O(CH 2) nSO mAr', (CH 2) nSO mA, (CH 2) nSO mN(R 3>)A, (CH 2) nSO mAr', NH(CH 2) nNH 2, NH(CH 2) nNHA, NH(CH 2) nNA 2, NA(CH 2) nNH 2, NA(CH 2) nNHA, NA(CH 2) nNA 2, O(CH 2) nHet 1> or Het 1>; R 3>H, A or (CH 2) nAr'; R 4>H, CN, OH, A, (CH 2) nAr', COR 3>, COAr', SO mA or SO mAr'; Ar' : phenyl optionally substituted with 1-5 of A, Ph, OH, OA, SH, SA, OPh, SPh, NH 2, NHA, NA 2, NHPh, Hal, NO 2, (CH 2) nCOOH, (CH 2) nCOOA, (CH 2) nCONH 2, (CH 2) nCONHA, CHO, COA, SO mA, SO mAPh, NHCOA, NHCOPh, NHSO 2A, NHSO 2Ph or SO 2NH 2; Ph : phenyl optionally substituted with 1-3 of A, Hal, CN, COOR (R is not defined), COOH, NH 2, NO 2, OH or OA; Het 1>monocyclic saturated heterocyclyl with 1-4 N, O and/or S atoms, optionally substituted with 1-3 of Hal, A, OA, (CH 2) nOH, (CH 2) nHal, NH 2, =NH, =NOH, =NOA and/or =O; A : 1-10C alkyl or haloalkyl; Hal : F, Cl, Br or I; n : 0-5; m : 0-2. Independent claims are also included for: (1) new compounds (I), namely 1-(2-methoxy-5-trifluoromethyl-phenyl)-3-(5-pyridin-4-ylmethyl-[1,3,4]thiadiazol-2-yl}-urea, 1-(5-chloro-2-methoxy-4-methyl-phenyl)-3-[5-(3,4-dimethoxybenzyl)-[1,3,4]thiadiazol-2-yl]-urea, 1-[5-(3,4-dimethoxybenzyl)-[1,3,4]thiadiazol-2-yl]-3-(3-trifluoromethoxy-phenyl)-urea, 1-[5-(1-phenyl-ethyl)-[1,3,4]thiadiazol-2-yl]-3-(3-trifluoromethylsulfonyl-phenyl)-urea, 1-[5-(3,4-dimethoxy-benzyl)-[1,3,4]thiadiazol-2-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-urea, 1-[5-(1-phenyl-ethyl)-(1,3,4]thiadiazol-2-yl]-3-p-tolyl-urea, 1-(2-methoxy-5-methyl-phenyl)-3-[5-(1-phenyl-ethyl)-[1,3,4]thiadiazol-2-yl]-urea, 1-(3-chloro-4-methyl-phenyl)-3-(5-(1-phenyl-ethyl)-[1,3,4]thiadiazol-2-yl]-urea, 1-(5-chloro-2-methyl-phenyl)-3-[5-(1-phenyl-ethyl)-[1,3,4]thiadiazol-2-yl]-urea, 1-(3-chloro-2-methyl-phenyl)-3-[5-(1-phenyl-ethyl)-[1,3,4]thiadiazol-2-yl]-urea, 1-(5-chloro-2-methoxy-phenyl)-3-[5-(1-phenyl-ethyl)-[1,3,4]thiadiazol-2-yl]-urea, 1-[5-(1-phenyl-ethyl)-[1,3,4]thiadiazol-2-yl]-3-(3-trifluoromethyl-phenyl)-urea, 1-[5-(1-phenyl-ethyl)-[1,3,4]thiadiazol-2-yl]-3-(4-trifluoromethyl-phenyl)-urea, 1-[5-(3,4-dimethoxy-benzyl)-[1,3,4]thiadiazol-2-yl]-3-(2-methoxy-phenyl)-urea, 1-[5-(1-phenyl-ethyl)-[1,3,4]thiadiazol-2-yl]-3-(4-trifluoromethoxy-phenyl)-urea, 1-(4-fluoro-3-trifluoromethyl-phenyl)-3-[5-(1-phenyl-ethyl)-[1,3,4]thiadiazol-2-yl]-urea, 1-(4-chloro-3-trifluoromethyl-phenyl)-3-[5-(1-phenyl-ethyl)-[1,3,4]thiadiazol-2-yl]-urea, 1-[5-(2.3-dimethoxy-benzyl)-[1,3,4]thiadiazol-2-yl]-3-(4-trifluoromethoxy-phenyl)-urea, 1-[5-(2,3-dimethoxy-benzyl)-[1,3,4]thiadiazol-2-yl]-3-(2-trifluoromethoxy-phenyl)-urea, 1-(5-chloro-2,4-dimethoxy-phenyl)-3-[5-(3,4-dimethoxy-benzyl)-[1,3,4]thiadiazol-2-yl]-urea, 1-(2,4-dimethoxy-phenyl) -3-[5-(1-phenyl-ethyl)-[1,3,4]thiadiazol-2-yl]-urea, 1-(3-chloro-4-methoxy-phenyl)-3-[5-(1-phenyl-ethyl)-[1,3,4]thiadiazol-2-yl]-urea, 1-[2-(2-dimethylamino-ethoxy)-5-trifluoromethyl-phenyl]-3-[5-(1-phenyl-ethyl)-[1,3,4]thiadiazol-2-yl]-urea; (2) a process for preparing the new compounds (I); (3) kit comprising a compound (I) and another drug in separate packaging. [Image] ACTIVITY : Cytostatic; Antipsoriatic; Gynecological; Antiinflammatory; Vulnerary; Antiarthritic; Antibacterial; Antiulcer; Virucide; Immunosuppressive; Anti-HIV. No biological data given. MECHANISM OF ACTION : Kinase inhibitor.
IPC 8 full level
A61K 31/433 (2006.01); A61K 31/4439 (2006.01); C07D 285/135 (2006.01); C07D 417/06 (2006.01); C07D 417/12 (2006.01); C07D 285/12 (2006.01)
CPC (source: EP US)
A61P 13/08 (2017.12 - EP); A61P 15/08 (2017.12 - EP); A61P 17/00 (2017.12 - EP); A61P 17/02 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 31/00 (2017.12 - EP); A61P 31/04 (2017.12 - EP); A61P 31/16 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 37/00 (2017.12 - EP); A61P 37/02 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 285/135 (2013.01 - EP US); C07D 417/06 (2013.01 - EP US); C07D 417/12 (2013.01 - EP US)
Citation (search report)
See references of WO 2005085220A1
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
DOCDB simple family (publication)
DE 102004009933 A1 20050915; AR 049773 A1 20060906; AU 2005219499 A1 20050915; CA 2557303 A1 20050915; EP 1720846 A1 20061115; JP 2007523922 A 20070823; US 2007191353 A1 20070816; WO 2005085220 A1 20050915
DOCDB simple family (application)
DE 102004009933 A 20040226; AR P050100704 A 20050225; AU 2005219499 A 20050131; CA 2557303 A 20050131; EP 05701263 A 20050131; EP 2005000908 W 20050131; JP 2007500082 A 20050131; US 59072905 A 20050131